Diiodothyropropionic acid in the management of cardiovascular disease

Shitij Arora, Manasi Agrawal, Jameel Iqbal, Peter Bhandari, Jeffrey I. Mechanick

Research output: Contribution to journalArticle

Abstract

Objective Cardiovascular disease is the leading cause of morbidity and mortality in the USA. Thyroid analogs have emerged as a potential new therapeutic agent for cardiovascular disease. Thyroid hormones beneficially influence cardiac contractility and serum lipids but can also confer harmful effects on cardiac tissue and bone. To circumvent these harmful effects of thyroid hormones, several thyroid analogs have been studied since the 1960s. This review focuses on one such thyroid analog, diiodothyropropionic acid (DITPA), which has shown promise in the management of heart failure. Materials and methods We conducted a systematic review of the literature using evidence-based criteria. Results Strong laboratory data exist supporting the role of DITPA in heart failure by improving systolic and diastolic heart function. DITPA significantly alters the myosin heavy chain ratio in the heart muscle to improve ventricular contractility. There is increasing evidence in support of the improvement in lipid profile in patients on DITPA. No proarrhythmogenic adverse effects were noted with the use of DITPA. Conclusion DITPA appears to be promising in enhancing cardiac output and hemodynamic stability for heart failure patients, with possible synergistic implications when combined with other heart failure medications. However, extensive human trials are needed to establish its role in the management of heart failure and establish its safety profile.

Original languageEnglish (US)
Pages (from-to)67-73
Number of pages7
JournalCardiovascular Endocrinology
Volume4
Issue number2
DOIs
StatePublished - May 26 2015

Fingerprint

Cardiovascular Diseases
Acids
Heart Failure
Diastolic Heart Failure
Systolic Heart Failure
Thyroid Gland
Thyroid Hormones
Lipids
Myosin Heavy Chains
Cardiac Output
Myocardium
Hemodynamics
Morbidity
Safety
Bone and Bones
Mortality
Serum
Therapeutics

Keywords

  • diiodothyropropionic acid
  • heart failure
  • hypercholesterolemia
  • T3
  • thyroid analogs

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrine and Autonomic Systems

Cite this

Diiodothyropropionic acid in the management of cardiovascular disease. / Arora, Shitij; Agrawal, Manasi; Iqbal, Jameel; Bhandari, Peter; Mechanick, Jeffrey I.

In: Cardiovascular Endocrinology, Vol. 4, No. 2, 26.05.2015, p. 67-73.

Research output: Contribution to journalArticle

Arora, Shitij ; Agrawal, Manasi ; Iqbal, Jameel ; Bhandari, Peter ; Mechanick, Jeffrey I. / Diiodothyropropionic acid in the management of cardiovascular disease. In: Cardiovascular Endocrinology. 2015 ; Vol. 4, No. 2. pp. 67-73.
@article{565852880cef4c51a6c975ad337d7e5c,
title = "Diiodothyropropionic acid in the management of cardiovascular disease",
abstract = "Objective Cardiovascular disease is the leading cause of morbidity and mortality in the USA. Thyroid analogs have emerged as a potential new therapeutic agent for cardiovascular disease. Thyroid hormones beneficially influence cardiac contractility and serum lipids but can also confer harmful effects on cardiac tissue and bone. To circumvent these harmful effects of thyroid hormones, several thyroid analogs have been studied since the 1960s. This review focuses on one such thyroid analog, diiodothyropropionic acid (DITPA), which has shown promise in the management of heart failure. Materials and methods We conducted a systematic review of the literature using evidence-based criteria. Results Strong laboratory data exist supporting the role of DITPA in heart failure by improving systolic and diastolic heart function. DITPA significantly alters the myosin heavy chain ratio in the heart muscle to improve ventricular contractility. There is increasing evidence in support of the improvement in lipid profile in patients on DITPA. No proarrhythmogenic adverse effects were noted with the use of DITPA. Conclusion DITPA appears to be promising in enhancing cardiac output and hemodynamic stability for heart failure patients, with possible synergistic implications when combined with other heart failure medications. However, extensive human trials are needed to establish its role in the management of heart failure and establish its safety profile.",
keywords = "diiodothyropropionic acid, heart failure, hypercholesterolemia, T3, thyroid analogs",
author = "Shitij Arora and Manasi Agrawal and Jameel Iqbal and Peter Bhandari and Mechanick, {Jeffrey I.}",
year = "2015",
month = "5",
day = "26",
doi = "10.1097/XCE.0000000000000046",
language = "English (US)",
volume = "4",
pages = "67--73",
journal = "Cardiovascular Endocrinology and Metabolism",
issn = "2574-0954",
publisher = "Lippincott Williams and Wilkins Ltd.",
number = "2",

}

TY - JOUR

T1 - Diiodothyropropionic acid in the management of cardiovascular disease

AU - Arora, Shitij

AU - Agrawal, Manasi

AU - Iqbal, Jameel

AU - Bhandari, Peter

AU - Mechanick, Jeffrey I.

PY - 2015/5/26

Y1 - 2015/5/26

N2 - Objective Cardiovascular disease is the leading cause of morbidity and mortality in the USA. Thyroid analogs have emerged as a potential new therapeutic agent for cardiovascular disease. Thyroid hormones beneficially influence cardiac contractility and serum lipids but can also confer harmful effects on cardiac tissue and bone. To circumvent these harmful effects of thyroid hormones, several thyroid analogs have been studied since the 1960s. This review focuses on one such thyroid analog, diiodothyropropionic acid (DITPA), which has shown promise in the management of heart failure. Materials and methods We conducted a systematic review of the literature using evidence-based criteria. Results Strong laboratory data exist supporting the role of DITPA in heart failure by improving systolic and diastolic heart function. DITPA significantly alters the myosin heavy chain ratio in the heart muscle to improve ventricular contractility. There is increasing evidence in support of the improvement in lipid profile in patients on DITPA. No proarrhythmogenic adverse effects were noted with the use of DITPA. Conclusion DITPA appears to be promising in enhancing cardiac output and hemodynamic stability for heart failure patients, with possible synergistic implications when combined with other heart failure medications. However, extensive human trials are needed to establish its role in the management of heart failure and establish its safety profile.

AB - Objective Cardiovascular disease is the leading cause of morbidity and mortality in the USA. Thyroid analogs have emerged as a potential new therapeutic agent for cardiovascular disease. Thyroid hormones beneficially influence cardiac contractility and serum lipids but can also confer harmful effects on cardiac tissue and bone. To circumvent these harmful effects of thyroid hormones, several thyroid analogs have been studied since the 1960s. This review focuses on one such thyroid analog, diiodothyropropionic acid (DITPA), which has shown promise in the management of heart failure. Materials and methods We conducted a systematic review of the literature using evidence-based criteria. Results Strong laboratory data exist supporting the role of DITPA in heart failure by improving systolic and diastolic heart function. DITPA significantly alters the myosin heavy chain ratio in the heart muscle to improve ventricular contractility. There is increasing evidence in support of the improvement in lipid profile in patients on DITPA. No proarrhythmogenic adverse effects were noted with the use of DITPA. Conclusion DITPA appears to be promising in enhancing cardiac output and hemodynamic stability for heart failure patients, with possible synergistic implications when combined with other heart failure medications. However, extensive human trials are needed to establish its role in the management of heart failure and establish its safety profile.

KW - diiodothyropropionic acid

KW - heart failure

KW - hypercholesterolemia

KW - T3

KW - thyroid analogs

UR - http://www.scopus.com/inward/record.url?scp=84954359351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954359351&partnerID=8YFLogxK

U2 - 10.1097/XCE.0000000000000046

DO - 10.1097/XCE.0000000000000046

M3 - Article

AN - SCOPUS:84954359351

VL - 4

SP - 67

EP - 73

JO - Cardiovascular Endocrinology and Metabolism

JF - Cardiovascular Endocrinology and Metabolism

SN - 2574-0954

IS - 2

ER -